This week, Ontario’s political landscape shifted dramatically as Premier Doug Ford secured a historic win, setting the stage for aggressive economic and healthcare policies in the face of mounting global uncertainty.
Following the Ontario elections, Premier Doug Ford’s Progressive Conservative Party secured a historic third consecutive majority government, winning 80 seats and 42.97% of the votes. The New Democratic Party, led by Marit Stiles, was confirmed as the official opposition with 27 seats, followed by the Liberals with 14 seats, and the Green Party maintained its two seats. During his victory speech, Ford reiterated his campaign calls for a “strong mandate” against the Trump administration’s economic threats, which triggered the $189-million snap election. Ford recalled his party’s promises to remove internal trade barriers, build Highway 413, and fast-track project approvals. He also stressed that Canada would never be the 51st state, vowing to fight against any U.S. tariff threats.
NDP Leader Marit Stiles thanked her supporters and acknowledged the possible disappointment with the election results. In a speech, Stiles celebrated with the party after the NDP was declared the official opposition. The Liberal Party failed to displace the NDP as the official opposition and settled for third place. Despite the loss, Liberal Leader Bonnie Crombie celebrated after regaining official party status. While Mike Schreiner, who led the Green Party, encouraged party supporters to organize despite the big PC victory.
This clear result comes at a time when Ontarians are increasingly aware of how global politics directly impact their day-to-day lives. A recent Nanos Research poll found that 45% of Ontarians see provincial and federal elections as equally important as U.S. President Donald Trump’s actions against Canada.
With this resounding win, his government’s ambitious Life Sciences Strategy is expected to move forward at full speed. Premier Doug Ford is expected to double down on this strategy to establish the province as a global biomanufacturing and life sciences hub. The $146-million Phase 2 Life Sciences Strategy pledged to accelerate biomanufacturing and medical innovation through targeted investments in research, venture capital, and workforce development with support from federal-provincial collaboration, workforce initiatives, digital health integration, and strategic industry partnerships.
Key allocations include $46 million to the Ontario Biosciences Research Infrastructure Fund for university and hospital research modernization, $40 million for the Venture Ontario Fund for life sciences venture capital, and $24 million for a Life Sciences Scale-Up Fund assisting companies like Synaptive Medical in production expansion. This effort is reinforced through federal collaboration, including a $16 million investment in southern Ontario’s life sciences sector. The strategy also addresses long-term talent development, with $705 million earmarked to expand post-secondary STEM capacity, alongside $165 million for apprenticeship programs focusing on biomanufacturing automation.
However, even as Ontario invests in its life sciences future, the sector faces mounting external risks from U.S. tariffs. In response, Life Sciences Ontario with Board Chair Alison Symington and key industry groups—including the Ontario Centre of Innovation, Medtech Canada, Innovative Medicines Canada, and other partners—launched the Life Sciences Tariff Task Force.
Jason Field, President and CEO of Life Sciences Ontario, highlighted the critical link between health and economic security, noting that tariffs affect not only the manufacturing of life science technologies but also clinical trials and cross-border research. He underscored the need for strategic solutions in the evolving healthcare landscape.
Similarly, the Canadian Pharmacists Association convened leaders from the Canadian pharmacy community to examine the immediate and long-term impacts of U.S. tariffs on Canadian pharmacies. While there is uncertainty surrounding the issue, the group highlighted the need for proactive strategies to address future challenges.
Meanwhile, rising drug costs are compounding pressures on businesses and employees alike. The Patented Medicine Prices Review Board reported that private drug plan costs jumped by 12.9% in 2023, driven by a 14.1% increase in drug spending largely due to the growing use of high-cost medicines. Medicines costing over $10,000 annually accounted for one-third of total drug costs despite being used by only 1.5% of claimants.
From 2018 to 2023, private drug plan expenditures grew at a 7.1% annual rate, driven by high-cost medicines and the top 5% of claimants, who accounted for nearly two-thirds of total drug costs. While cost-saving measures like generics helped curb expenses, private plans covered larger prescription supplies and reimbursed 84% of new active substances, with small sponsors making up most plans but large plans covering 90% of total drug costs.
Amid these mounting pressures, Newfoundland and Labrador Premier Andrew Furey announced his resignation after nearly five years in office, citing the demands of the job and rising uncertainty over U.S. trade policy under Trump. Furey, who spearheaded a historic energy deal with Quebec and led efforts to boost the province’s population, said he plans to return to his surgical career. Ontario Premier Doug Ford and New Brunswick Premier Susan Holt both praised Furey’s leadership, highlighting his accessibility, advice, and strong advocacy for Newfoundland and Labrador and Canada.
Canadians continue to brace for evolving trade tensions, domestic affordability pressures, and growing healthcare concerns.
You can now book a free consultation to learn more about our Executive Daily Briefing and how it can help you anticipate risks, spot opportunities, and act with confidence.
